Cargando…

Transmitted Drug Resistance Mutations in Antiretroviral-Naïve Injection Drug Users with Chronic HIV-1 Infection in Iran

The growing incidence and transmission of drug resistant HIV-1 strains due to widespread use of antiretroviral therapy (ART) can jeopardize the success of first-line ART. While there is a known moderate prevalence of transmitted drug resistance (TDR) among newly infected Iranians, no data exist abou...

Descripción completa

Detalles Bibliográficos
Autores principales: Memarnejadian, Arash, Menbari, Shahoo, Mansouri, Seyed Ali, Sadeghi, Leila, Vahabpour, Rouhollah, Aghasadeghi, Mohammad Reza, Mostafavi, Ehsan, Abdi, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427455/
https://www.ncbi.nlm.nih.gov/pubmed/25962088
http://dx.doi.org/10.1371/journal.pone.0126955
_version_ 1782370732262555648
author Memarnejadian, Arash
Menbari, Shahoo
Mansouri, Seyed Ali
Sadeghi, Leila
Vahabpour, Rouhollah
Aghasadeghi, Mohammad Reza
Mostafavi, Ehsan
Abdi, Mohammad
author_facet Memarnejadian, Arash
Menbari, Shahoo
Mansouri, Seyed Ali
Sadeghi, Leila
Vahabpour, Rouhollah
Aghasadeghi, Mohammad Reza
Mostafavi, Ehsan
Abdi, Mohammad
author_sort Memarnejadian, Arash
collection PubMed
description The growing incidence and transmission of drug resistant HIV-1 strains due to widespread use of antiretroviral therapy (ART) can jeopardize the success of first-line ART. While there is a known moderate prevalence of transmitted drug resistance (TDR) among newly infected Iranians, no data exist about the rate of these primary resistance mutations among the ART-naïve, chronically infected individuals who are, in fact, the main candidates for ART initiation. To address this issue, we collected blood samples from 40 ART-naïve injection drug-users (IDUs) with chronic HIV-1 infection (seroconversion time ranging from 2 to 9 years) living in Sanandaj, Iran, followed by sequencing of the protease and reverse-transcriptase regions from their HIV-1 genome. Phylogenetic analyses of the sequenced regions revealed that all samples were CRF35_AD. Transmitted resistance mutations were interpreted as surveillance drug-resistant mutations (SDRMs) based on the world health organization (WHO) algorithm. The frequency of SDRMs to any class of antiretroviral drugs was 15%, which included mutations to nucleoside reverse transcriptase inhibitors (NRTIs, 10%), with M41L and M184V as the most common (5%), and non-nucleoside reverse transcriptase inhibitors (NNRTIs, 5%), with K103N as the only detected mutation (5%). Although not in the WHO SDRMs list, several minor protease inhibitor resistant mutations listed in the International Antiviral Society-USA panel were identified, of which M36I, H69K, L89M/V/I (each one 100%) and K20R/T (92.5%) can be considered as polymorphic signatures for CRF35_AD.The relatively high rate of TDR mutations in our study raises concerns about the risk of treatment failure in chronically infected IDUs of Sanandaj city. These results suggest that routine resistance testing should be considered before the therapy initiation in this area. Additional surveillance studies are required to generalize this deduction to other cities of Iran.
format Online
Article
Text
id pubmed-4427455
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-44274552015-05-21 Transmitted Drug Resistance Mutations in Antiretroviral-Naïve Injection Drug Users with Chronic HIV-1 Infection in Iran Memarnejadian, Arash Menbari, Shahoo Mansouri, Seyed Ali Sadeghi, Leila Vahabpour, Rouhollah Aghasadeghi, Mohammad Reza Mostafavi, Ehsan Abdi, Mohammad PLoS One Research Article The growing incidence and transmission of drug resistant HIV-1 strains due to widespread use of antiretroviral therapy (ART) can jeopardize the success of first-line ART. While there is a known moderate prevalence of transmitted drug resistance (TDR) among newly infected Iranians, no data exist about the rate of these primary resistance mutations among the ART-naïve, chronically infected individuals who are, in fact, the main candidates for ART initiation. To address this issue, we collected blood samples from 40 ART-naïve injection drug-users (IDUs) with chronic HIV-1 infection (seroconversion time ranging from 2 to 9 years) living in Sanandaj, Iran, followed by sequencing of the protease and reverse-transcriptase regions from their HIV-1 genome. Phylogenetic analyses of the sequenced regions revealed that all samples were CRF35_AD. Transmitted resistance mutations were interpreted as surveillance drug-resistant mutations (SDRMs) based on the world health organization (WHO) algorithm. The frequency of SDRMs to any class of antiretroviral drugs was 15%, which included mutations to nucleoside reverse transcriptase inhibitors (NRTIs, 10%), with M41L and M184V as the most common (5%), and non-nucleoside reverse transcriptase inhibitors (NNRTIs, 5%), with K103N as the only detected mutation (5%). Although not in the WHO SDRMs list, several minor protease inhibitor resistant mutations listed in the International Antiviral Society-USA panel were identified, of which M36I, H69K, L89M/V/I (each one 100%) and K20R/T (92.5%) can be considered as polymorphic signatures for CRF35_AD.The relatively high rate of TDR mutations in our study raises concerns about the risk of treatment failure in chronically infected IDUs of Sanandaj city. These results suggest that routine resistance testing should be considered before the therapy initiation in this area. Additional surveillance studies are required to generalize this deduction to other cities of Iran. Public Library of Science 2015-05-11 /pmc/articles/PMC4427455/ /pubmed/25962088 http://dx.doi.org/10.1371/journal.pone.0126955 Text en © 2015 Memarnejadian et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Memarnejadian, Arash
Menbari, Shahoo
Mansouri, Seyed Ali
Sadeghi, Leila
Vahabpour, Rouhollah
Aghasadeghi, Mohammad Reza
Mostafavi, Ehsan
Abdi, Mohammad
Transmitted Drug Resistance Mutations in Antiretroviral-Naïve Injection Drug Users with Chronic HIV-1 Infection in Iran
title Transmitted Drug Resistance Mutations in Antiretroviral-Naïve Injection Drug Users with Chronic HIV-1 Infection in Iran
title_full Transmitted Drug Resistance Mutations in Antiretroviral-Naïve Injection Drug Users with Chronic HIV-1 Infection in Iran
title_fullStr Transmitted Drug Resistance Mutations in Antiretroviral-Naïve Injection Drug Users with Chronic HIV-1 Infection in Iran
title_full_unstemmed Transmitted Drug Resistance Mutations in Antiretroviral-Naïve Injection Drug Users with Chronic HIV-1 Infection in Iran
title_short Transmitted Drug Resistance Mutations in Antiretroviral-Naïve Injection Drug Users with Chronic HIV-1 Infection in Iran
title_sort transmitted drug resistance mutations in antiretroviral-naïve injection drug users with chronic hiv-1 infection in iran
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427455/
https://www.ncbi.nlm.nih.gov/pubmed/25962088
http://dx.doi.org/10.1371/journal.pone.0126955
work_keys_str_mv AT memarnejadianarash transmitteddrugresistancemutationsinantiretroviralnaiveinjectiondruguserswithchronichiv1infectioniniran
AT menbarishahoo transmitteddrugresistancemutationsinantiretroviralnaiveinjectiondruguserswithchronichiv1infectioniniran
AT mansouriseyedali transmitteddrugresistancemutationsinantiretroviralnaiveinjectiondruguserswithchronichiv1infectioniniran
AT sadeghileila transmitteddrugresistancemutationsinantiretroviralnaiveinjectiondruguserswithchronichiv1infectioniniran
AT vahabpourrouhollah transmitteddrugresistancemutationsinantiretroviralnaiveinjectiondruguserswithchronichiv1infectioniniran
AT aghasadeghimohammadreza transmitteddrugresistancemutationsinantiretroviralnaiveinjectiondruguserswithchronichiv1infectioniniran
AT mostafaviehsan transmitteddrugresistancemutationsinantiretroviralnaiveinjectiondruguserswithchronichiv1infectioniniran
AT abdimohammad transmitteddrugresistancemutationsinantiretroviralnaiveinjectiondruguserswithchronichiv1infectioniniran